HPS3/TIMI 55 REVEAL

HPS3/TIMI 55 REVEAL will assess the effect of Cholesteryl ester transfer protein (CETP) inhibition with anacetrapib 100 mg versus matching placebo on time to first major coronary event among 30,000 individuals with pre-existing vascular disease.

LINK TO CLINICALTRIALS.GOV